StockData

Aemetis vs Gevo

AMTX and GEVO side by side, both in chemicals and allied products. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMTX and GEVO compare

Gevo is the larger company, worth 5.1 times as much as Aemetis ($430M against $85.2M).

Gevo grew revenue faster over the last twelve months (121% versus −1.7% for Aemetis).

Aemetis keeps more of each dollar of sales as profit, with a net margin of −27.4% compared with −120% at Gevo.

Gevo scores higher on the StockData Score (8 against 4 for Aemetis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMTXGEVO
Size and price
Market cap$85.2M$430M
Share price$1.18$1.74
Change, 1 year−39.5%−13.0%
Change, 5 years−93.3%−69.7%
Beta (5Y)−2.72−0.30
Employees220151
StockData Score
Total score48 (better)
Valuation score12 (better)
Growth score24 (better)
Performance score11
Health score01 (better)
Dividend score00
Valuation
P/S0.4× (better)2.4×
P/B–1.6×
FCF yield−46.2%−13.2% (better)
Fair value–$2.40
Margin of safety–27.5%
Growth
Revenue growth (TTM)−1.7%121% (better)
Revenue growth, 5Y average3.6%96.1% (better)
Profitability
Gross margin10.9%47.3% (better)
Operating margin−5.3% (better)−103%
Net margin−27.4% (better)−120%
FCF margin−17.9% (better)−31.9%
Return on equity–−57.0%
Return on invested capital−12.5% (better)−29.8%
Financial health
Debt / equity–0.61
Interest coverage−0.2× (better)−8.8×
Current ratio0.082.70 (better)
Altman Z-score−4.12−2.42 (better)
Piotroski F-score44
Dividends and buybacks
Buyback yield−28.0%–
Shareholder yield−28.0%0.00% (better)
Ownership
Held by institutions24.5%37.2%
Held by insiders10.9%4.8%
Insider net buying, 12 months−$20.5K (better)−$2.5M
Short interest, % of float13.1%10.6%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.